Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

MK-0536 Inhibits HIV-1 Integrases Resistant to Raltegravir

30 Aug 2011

Abstract excerpt

With the U.S. Food and Drug Administration approval of raltegravir (RAL; MK-0518; Merck & Co.), HIV-1 integrase (IN) is the newest therapeutic target for AIDS and HIV infections. Recent structural analyses show that IN strand transfer inhibitors (INSTIs) share a common binding mode in the enzyme active site. While RAL represents a therapeutic breakthrough, the emergence of IN resistance mutations imposes the...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Biochemical and Molecular Research
Share to HIV/AIDS drug development and treatment
Share to HIV Research and Treatment

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 21876054
DOI: 10.1128/aac.05288-11

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

MK-0536 Inhibits HIV-1 Integrases Resistant to RaltegravirPMID 21876054Read ↗

Structural and functional analyses of the second-generation integrase strand transfer inhibitor dolutegravir (S/GSK1349572).Semantic proximity Read ↗

Molecular mechanisms of retroviral integrase inhibition and the evolution of viral resistance.Semantic proximity Read ↗

Patterns of resistance development with integrase inhibitors in HIVSemantic proximity Read ↗

HIV-1 Integrase Strand Transfer Inhibitors with Reduced Susceptibility to Drug Resistant Mutant IntegrasesSemantic proximity Read ↗

Resistance to Integrase InhibitorsSemantic proximity Read ↗

The G140S mutation in HIV integrases from raltegravir-resistant patients rescues catalytic defect due to the resistance Q148H mutationSemantic proximity Read ↗

Molecular dynamics approaches estimate the binding energy of HIV-1 integrase inhibitors and correlate with in vitro activity.Semantic proximity Read ↗

Impact of resistance mutations on inhibitor binding to HIV-1 integrase.Semantic proximity Read ↗

3-Hydroxypyrimidine-2,4-diones as an inhibitor scaffold of HIV integrase.Semantic proximity Read ↗

Resistance to raltegravir highlights integrase mutations at codon 148 in conferring cross-resistance to a second-generation HIV-1 integrase inhibitor.Semantic proximity Read ↗

Biological and structural analysis of new potent Integrase-LEDGF allosteric HIV-1 inhibitorsSemantic proximity Read ↗

4-amino-1-hydroxy-2-oxo-1,8-naphthyridine-containing compounds having high potency against raltegravir-resistant integrase mutants of HIV-1.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.